vs
Hippo Holdings Inc.（HIPO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Hippo Holdings Inc.的1.1倍（$127.1M vs $120.4M），Hippo Holdings Inc.同比增速更快（18.2% vs 17.1%），Hippo Holdings Inc.自由现金流更多（$9.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 18.9%）
河马谷庄园是一座甘蔗种植园，坐落于津巴布韦东南部奇雷济区奇雷济镇附近，位于伦迪河沿岸，毗邻莫桑比克边境，是当地重要的蔗糖产业园区。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
HIPO vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$120.4M
营收增速更快
HIPO
高出1.0%
17.1%
自由现金流更多
HIPO
多$35.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
18.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.4M | $127.1M |
| 净利润 | $6.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 5.6% | -54.6% |
| 净利率 | 5.0% | — |
| 营收同比 | 18.2% | 17.1% |
| 净利润同比 | -86.4% | — |
| 每股收益（稀释后） | $0.31 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HIPOZLAB
| Q4 25 | $120.4M | $127.1M | ||
| Q3 25 | $120.6M | $115.4M | ||
| Q2 25 | $117.3M | $109.1M | ||
| Q1 25 | $110.3M | $105.7M | ||
| Q4 24 | $101.9M | $108.5M | ||
| Q3 24 | $95.5M | $101.8M | ||
| Q2 24 | $89.6M | $100.1M | ||
| Q1 24 | $85.1M | $87.1M |
净利润HIPOZLAB
| Q4 25 | $6.0M | — | ||
| Q3 25 | $98.1M | $-36.0M | ||
| Q2 25 | $1.3M | $-40.7M | ||
| Q1 25 | $-47.7M | $-48.4M | ||
| Q4 24 | $44.2M | — | ||
| Q3 24 | $-8.5M | $-41.7M | ||
| Q2 24 | $-40.5M | $-80.3M | ||
| Q1 24 | $-35.7M | $-53.5M |
毛利率HIPOZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率HIPOZLAB
| Q4 25 | 5.6% | -54.6% | ||
| Q3 25 | 81.3% | -42.3% | ||
| Q2 25 | 3.4% | -50.3% | ||
| Q1 25 | -41.3% | -53.3% | ||
| Q4 24 | 46.3% | -62.6% | ||
| Q3 24 | -5.4% | -66.6% | ||
| Q2 24 | -40.7% | -76.0% | ||
| Q1 24 | -38.7% | -80.7% |
净利率HIPOZLAB
| Q4 25 | 5.0% | — | ||
| Q3 25 | 81.3% | -31.2% | ||
| Q2 25 | 1.1% | -37.3% | ||
| Q1 25 | -43.2% | -45.8% | ||
| Q4 24 | 43.4% | — | ||
| Q3 24 | -8.9% | -40.9% | ||
| Q2 24 | -45.2% | -80.2% | ||
| Q1 24 | -42.0% | -61.4% |
每股收益（稀释后）HIPOZLAB
| Q4 25 | $0.31 | $-0.05 | ||
| Q3 25 | $3.77 | $-0.03 | ||
| Q2 25 | $0.05 | $-0.04 | ||
| Q1 25 | $-1.91 | $-0.04 | ||
| Q4 24 | $1.81 | $-0.09 | ||
| Q3 24 | $-0.34 | $-0.04 | ||
| Q2 24 | $-1.64 | $-0.08 | ||
| Q1 24 | $-1.47 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $218.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $436.1M | $715.5M |
| 总资产 | $1.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HIPOZLAB
| Q4 25 | $218.3M | $689.6M | ||
| Q3 25 | $247.7M | $717.2M | ||
| Q2 25 | $198.9M | $732.2M | ||
| Q1 25 | $140.9M | $757.3M | ||
| Q4 24 | $197.6M | $779.7M | ||
| Q3 24 | $191.2M | $616.1M | ||
| Q2 24 | $175.9M | $630.0M | ||
| Q1 24 | $223.4M | $650.8M |
股东权益HIPOZLAB
| Q4 25 | $436.1M | $715.5M | ||
| Q3 25 | $421.5M | $759.9M | ||
| Q2 25 | $332.5M | $791.7M | ||
| Q1 25 | $322.8M | $810.8M | ||
| Q4 24 | $362.1M | $840.9M | ||
| Q3 24 | $326.4M | $667.7M | ||
| Q2 24 | $322.6M | $704.2M | ||
| Q1 24 | $351.2M | $762.2M |
总资产HIPOZLAB
| Q4 25 | $1.9B | $1.2B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.5B | $1.2B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $985.3M | ||
| Q2 24 | $1.5B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 7.6% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.53× | — |
| 过去12个月自由现金流最近4个季度 | $14.8M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流HIPOZLAB
| Q4 25 | $9.2M | $-26.0M | ||
| Q3 25 | $16.9M | $-32.0M | ||
| Q2 25 | $24.7M | $-31.0M | ||
| Q1 25 | $-35.6M | $-61.7M | ||
| Q4 24 | $47.5M | $-55.8M | ||
| Q3 24 | $46.8M | $-26.8M | ||
| Q2 24 | $-10.6M | $-42.2M | ||
| Q1 24 | $17.7M | $-90.1M |
自由现金流HIPOZLAB
| Q4 25 | $9.1M | $-26.7M | ||
| Q3 25 | $16.8M | $-35.0M | ||
| Q2 25 | $24.6M | $-33.9M | ||
| Q1 25 | $-35.7M | $-63.2M | ||
| Q4 24 | $47.2M | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | $-10.7M | $-42.9M | ||
| Q1 24 | $17.6M | $-91.1M |
自由现金流率HIPOZLAB
| Q4 25 | 7.6% | -21.0% | ||
| Q3 25 | 13.9% | -30.4% | ||
| Q2 25 | 21.0% | -31.1% | ||
| Q1 25 | -32.4% | -59.9% | ||
| Q4 24 | 46.3% | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | -11.9% | -42.9% | ||
| Q1 24 | 20.7% | -104.5% |
资本支出强度HIPOZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.3% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
现金转化率HIPOZLAB
| Q4 25 | 1.53× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 19.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HIPO
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
